We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BMG LABTECH

BMG LABTECH is a manufacturer of a wide range of dedicated and multi-mode microplate instruments ranging from single-... read more Featured Products: More products

Download Mobile App




Rapid Method Detects Creutzfeldt-Jakob Disease in Cerebrospinal Fluid

By LabMedica International staff writers
Posted on 05 May 2015
A long-standing problem in dealing with various neurodegenerative protein misfolding diseases is early and accurate diagnosis and this is particularly important with human prion diseases.

Real-time quaking-induced conversion (RT-QuIC) assays of cerebrospinal fluid (CSF) and nasal-brushing specimens are valuable in distinguishing Creutzfeldt-Jakob Disease (CJD) from non-CJD conditions but require more than two days and up to five days to complete. More...


Scientists at the National Institutes of Health, (NIH; Hamilton, Montana, USA) and their colleagues obtained cerebrospinal fluid samples from patients with possible or probable Creutzfeldt-Jakob disease at the time of sampling, as well as from the patients with other neurologic disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis, atypical Parkinsonism, dementia, dystonia, and seven other neurologic disorders.

RT-QuIC assays were performed on the CSF samples. Reaction mixtures was loaded into a black 96-well plate with a clear bottom and reaction mixtures were seeded with CSF for a final reaction volume of 100 µL. Plates were sealed and incubated in a BMG FLUOstar Omega plate reader (BMG LABTECH; Ortenberg, Germany; www.bmglabtech.com) at either 42 °C or 55 °C for 55 to 90 hours with cycles of 60 seconds of shaking and 60 seconds of rest throughout the incubation. Thioflavin T fluorescence measurements, excitation, 450 ± 10 nm; emission, 480 ± 10 nm, were taken every 45 minutes.

The improved RT-QuIC assay identified positive CSF samples within four to 14 hours with better analytical sensitivity. Moreover, analysis of 11 CJD patients demonstrated that while seven were RT-QuIC positive using the previous conditions, 10 were positive using the new assay. In these and further analyses, a total of 46 of 48 CSF samples from sporadic CJD patients were positive, while all 39 non-CJD patients were negative, giving 95.8% diagnostic sensitivity and 100% specificity.

The authors concluded that they had markedly improved RT-QuIC analysis of human CSF such that CJD and non-CJD patients can be discriminated in a matter of hours rather than days with enhanced sensitivity. These improvements should allow for much faster, more accurate, and practical testing for CJD. In broader terms, the study provides a prototype for tests for misfolded protein aggregates that cause many important amyloid diseases, such as Alzheimer’s, Parkinson’s, and tauopathies. The study was originally published on January 20, 2015, in the journal mBio.

Related Links:

US National Institutes of Health
BMG LABTECH




New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.